Vertex, Inc.VERXEarnings & Financial Report
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
VERX Q1 FY2026 Key Financial Metrics
Revenue
$196.6M
Gross Profit
$124.9M
Operating Profit
$61.2M
Net Profit
$-2.5M
Gross Margin
63.5%
Operating Margin
31.1%
Net Margin
-1.3%
YoY Growth
11.1%
EPS
$-0.02
Vertex, Inc. Q1 FY2026 Financial Summary
Vertex, Inc. reported revenue of $196.6M (up 11.1% YoY) for Q1 FY2026, with a net profit of $-2.5M (down 122.6% YoY) (-1.3% margin). Cost of goods sold was $71.8M, operating expenses totaled $63.7M.
Key Financial Metrics
| Total Revenue | $196.6M |
|---|---|
| Net Profit | $-2.5M |
| Gross Margin | 63.5% |
| Operating Margin | 31.1% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Vertex, Inc. Q1 FY2026 revenue of $196.6M breaks down across 2 segments, led by Software subscriptions at $167.1M (85.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Software subscriptions | $167.1M | 85.0% |
| Services | $29.5M | 15.0% |
Vertex, Inc. Annual Revenue by Year
Vertex, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $748.4M).
Vertex, Inc. Quarterly Revenue & Net Profit History
Vertex, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $196.6M | +11.1% | $-2.5M | -1.3% |
| Q4 FY2025 | $194.7M | +9.1% | $-7.0M | -3.6% |
| Q3 FY2025 | $192.1M | +12.7% | $4.0M | 2.1% |
| Q2 FY2025 | $184.6M | +14.6% | $-961.0K | -0.5% |
| Q1 FY2025 | $177.1M | +12.9% | $11.1M | 6.3% |
| Q4 FY2024 | $178.5M | +15.2% | $-67.8M | -38.0% |
| Q3 FY2024 | $170.4M | +17.5% | $7.2M | 4.2% |
| Q2 FY2024 | $161.1M | +15.3% | $5.2M | 3.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $161.1M | $170.4M | $178.5M | $177.1M | $184.6M | $192.1M | $194.7M | $196.6M |
| YoY Growth | 15.3% | 17.5% | 15.2% | 12.9% | 14.6% | 12.7% | 9.1% | 11.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.02B | $1.19B | $1.17B | $1.15B | $1.20B | $1.22B | $1.27B | $1.21B |
| Liabilities | $790.7M | $931.8M | $987.4M | $953.7M | $950.1M | $957.4M | $1.01B | $967.9M |
| Equity | $233.1M | $259.0M | $179.4M | $200.5M | $248.0M | $264.5M | $258.9M | $246.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $57.7M | $41.4M | $41.1M | $14.8M | $46.0M | $62.5M | $42.3M | $38.0M |